Assembly Biosciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ASMB research report →
Companywww.assemblybio.com
Assembly Biosciences, Inc. , a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection.
- CEO
- Jason A. Okazaki
- IPO
- 2010
- Employees
- 73
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $420.20M
- P/E
- -70.01
- P/S
- 5.91
- P/B
- 2.25
- EV/EBITDA
- -33.29
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 77.24%
- Op Margin
- -19.05%
- Net Margin
- -8.98%
- ROE
- -4.21%
- ROIC
- -6.74%
Growth & Income
- Revenue
- $72.30M · 153.52%
- Net Income
- $-6,122,000 · 84.76%
- EPS
- $-0.55 · 91.78%
- Op Income
- $-12,118,000
- FCF YoY
- 19.52%
Performance & Tape
- 52W High
- $39.71
- 52W Low
- $13.13
- 50D MA
- $28.67
- 200D MA
- $28.81
- Beta
- 1.09
- Avg Volume
- 105.23K
Get TickerSpark's AI analysis on ASMB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 29, 26 | Bjorkquist Jeanette M | other | 6,500 |
| Mar 30, 26 | Bjorkquist Jeanette M | sell | 312 |
| Mar 30, 26 | Bjorkquist Jeanette M | sell | 16 |
| Mar 29, 26 | White Nicole S | other | 26,000 |
| Mar 30, 26 | White Nicole S | sell | 188 |
| Mar 30, 26 | White Nicole S | sell | 9 |
| Mar 29, 26 | Gaggar Anuj | other | 26,000 |
| Mar 29, 26 | Delaney William E IV | other | 26,000 |
| Mar 29, 26 | Okazaki Jason A | other | 94,250 |
| Aug 8, 25 | GILEAD SCIENCES, INC. | buy | 2,295,920 |
Our ASMB Coverage
We haven't published any research on ASMB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ASMB Report →